key: cord-0894510-ggnn92xq authors: Zendjebil, Sandra; Zeitouni, Michel; Batonga, Marc; El Beze, Nathan; Guedeney, Paul; Collet, Jean-Philippe; Choussat, Rémi; Silvain, Johanne; Montalescot, Gilles title: Acute multi-vessel coronary occlusion revealing COVID-19 in a young adult date: 2020-06-09 journal: JACC Case Rep DOI: 10.1016/j.jaccas.2020.06.002 sha: 04068fde7da1b180340ddaa682ba3157470d1ca9 doc_id: 894510 cord_uid: ggnn92xq Abstract A 42-year-old man was admitted for a ST-segment elevation myocardial infarction revealing an acute thrombosis of the left anterior descending and right coronary arteries. Following this acute multivessel coronary occlusion in a young individual at low cardiovascular risk, he was tested positive for severe acute respiratory syndrome coronavirus 2. Myocardial infarction, acute coronary syndrome, arterial thrombosis, Coronavirus disease 2019, SARS-CoV-2 Abbreviations list COVID-19: Coronavirus disease 2019 DAPT: Double antiplatelet therapy ECG: electrocardiogram SARS-CoV-2: severe acute respiratory syndrome coronavirus 2 STEMI: ST-segment elevation myocardial infarction ULN: Upper limit of normal value A 42-year-old man was admitted for a ST-segment elevation myocardial infarction revealing an acute thrombosis of the left anterior descending and right coronary arteries. Following this acute multivessel coronary occlusion in a young individual at low cardiovascular risk, he was tested positive for severe acute respiratory syndrome coronavirus 2. A 42-year-old man without significant prior medical history was admitted to the catheterization laboratory for a ST-segment elevation myocardial infarction (STEMI). He had felt a constrictive chest pain for the past four hours. He reported a single episode of fever at 38.0°C two weeks prior to the event, with no other symptoms. He had no signs of shock, shortness of breath or fever. His physical examination was normal, with no sign of heart failure, pneumonia or deep venous thrombosis. The patient reported an active lifestyle with a history of playing competitive football and had a body mass index of 27 kg/m 2 . He had no significant medical history except for past smoking (20 pack-years) which he had quit two years before. He had no family history of cardiovascular disease and was on no medication or drugs. There was no possible other diagnosis as the presentation was clearly a STEMI. The initial electrocardiogram (ECG) displayed a sinus rhythm with an anterior ST-segment elevation and Q waves with negative T waves in the inferior leads. The initial echocardiography showed a large anterior, apical and inferior sequela with a reduced left ventricular ejection fraction of 40%, without right ventricular dysfunction. The contrast echocardiography ruled out a patent foramen ovale. The chest X-ray was normal. Leiden V mutation as well as protein S and C deficits and antiphospholipid syndrome were ruled out. Toxicological screening in urine showed no recent toxic consumption. The patient did not present any arrhythmic episode during the 4-day hospital stay. A dual antiplatelet therapy (DAPT) with aspirin and ticagrelor was initiated prior to hospital admission, as well as enoxaparin which was prolonged during the hospital stay. A glycoprotein IIbIIIa inhibitor was prescribed during the procedure. The patient was discharged with DAPT and was provided with protective measures to prevent any transmission of coronavirus disease 2019 (COVID-19) before discharge. Myocardial infarction in young adults is an increasing public health issue. The typical profile of these individuals involves patients with active smoking, high LDL cholesterol levels or a premature familial history of coronary artery disease. It traditionally features a single-vessel disease with a localized thrombotic occlusion, whereas other arteries display a normal angiographic aspect (1). Nonetheless, this individual with a low cardiovascular risk presented with two simultaneous acute occlusions of two coronary arteries of thrombotic and not embolic angiographic aspect. This suggests a significant thrombus burden that could have been triggered by COVID-19. symptoms, COVID-19 is now well described as a pro-thrombotic disease with a high prevalence of thromboembolic venous complications, as well as acute arterial ischemic events. Myocardial infarction related to COVID-19 seems to be common, as suggested by a recently published series (2) . The inflammatory state induced by SARS-COV-2 is indeed described as associated with a higher local immune response and more frequent atherosclerotic plaque erosions or ruptures causing type 1 myocardial infarction. Adjunctive factors such as hypoxemia or endothelial injury induced by the cytokine storm could play an important part in the process. Of note, other respiratory viruses, such as influenza viruses, are associated with more frequent myocardial infarction (3). Indeed, local inflammation inside the plaques can boost the production of collagenase by macrophages, therefore degrading and weakening the fibrous cap, which can induce plaque rupture and thrombotic acute coronary syndrome. Nevertheless, myocardial infarction in such infectious settings is not always tied to severe clinical or biological signs of sepsis. In fact, an observational study of 2287 patients presenting with myocardial infarction during a pneumonia, found that 16% of the patients had no sign of sepsis (4). In the present case, the patient presented with negative D-dimers but a high level of fibrinogen. Moreover, the concomitant occlusion of two coronary arteries is a good illustration of the prothrombotic state likely induced by COVID-19. The hypothesis of the thrombotic role of COVID-19 is reinforced by the exclusion of other diagnoses such as multiple emboli associated with atrial fibrillation or a patent foramen ovale. Similarly, no thrombophilia was detected. Interestingly, this patient featured almost no COVID-19 symptom prior to myocardial infarction, except for a transient feverish episode, spontaneously regressive within a few hours. Stefanini and colleagues' recent series showed that 85.7% of the Lombard COVID-19 infected patients with cardiovascular risk factors presenting for STEMI did not show any infectious symptom before myocardial infarction (5) . These observations suggest that ischemic events jeopardize patients infected with SARS-CoV-2, even when they have asymptomatic forms and are at low cardiovascular risk. The patient did not develop heart failure, nor heart rhythm disturbances or other complications of myocardial infarction. Furthermore, he remained free of COVID-19 symptoms. In the context of the COVID-19 pandemic, unusual myocardial infarction presentations -such as in young individuals at low cardiovascular risk -should lead to testing for SARS-CoV-2, even in asymptomatic patients. Because of the pro-thrombotic and inflammatory status enhanced by viral infection, COVID-19 is associated with a multitude of ischemic events, among which STEMI remains common. ST-segment elevation myocardial infarction with a high thrombus burden can appear as the first and only onset of COVID-19 symptoms. Plaque rupture in predisposed patients with cardiovascular risk factors can be enhanced by severe inflammation and worsened by pro-thrombotic characteristics of this new infectious disease. In the course of this COVID-19 pandemic, SARS-CoV-2 should probably be ruled out in patients with unusual or severe thrombotic and ischemic events, even when there are no symptoms of COVID-19. Long-Term Evolution of Premature Coronary Artery Disease ST-Segment Elevation in Patients with Covid-19 -A Case Series Acute Infection and Myocardial Infarction Cardiac Complications in Patients With Community-Acquired Pneumonia: Incidence, Timing, Risk Factors, and Association With Short-Term Mortality ST-Elevation Myocardial Infarction in Patients with COVID-19: Clinical and Angiographic Outcomes